New research backs CDY’s MK plan for osteoporosis
Cellmid (ASX:CDY) has received a boost with more academic research backing its midkine antibody’s potential in improving bone quality and fracture healing in osteoporosis models.
It told its shareholders today that a team of German researchers had found that MK antibodies could help in the healing of fractured bones in a validated model of osteoporosis in rodents – with the research published in journal PLoS One.
A previous study by the same researchers found that CDY’s MK antibody accelerated bone fracture healing in otherwise normal rodents.
Lead researcher Dr Astrid Liedert found that the application of CDY’s MK antibody in the rodent osteoporosis model improved the rate of fracture healing in both normal and osteoporotic animals.
The studies are still at a very early stage and any antibodies could still be a fair way off commercialisation – investors should consult a professional financial advisor before investing.
Dr Liedert also made the observation that the loss of bone mineral density and volume in otherwise intact but osteoporotic bones “some distance away” from the fracture site was reversed following the MK application.
The findings further cements CDY’s MK antibodies, which were found to accelerate bone healing in osteoporotic settings.
The upshot is that the MK antibodies could potentially be used by elderly patients with osteoporosis to help bone healing.
Osteoporotic patients have reduced bone regeneration capabilities, making bone healing especially difficult – and 30% of post-menopausal women suffer osteoporotic fractures after the age of 50.
Apart from the quality of life issues associated with fractures taking longer to heal, fractures can often cause severe and potentially life threatening complications for elderly patients.
The MK antibodies are under CDY’s subsidiary Lyramid, and CDY has filed patent applications covering the use of MK antibodies for fracture healing and restoring bone loss due to osteoporosis.
MK has been shown to be an important early marker for diagnosing various diseases and is only evident in a disease context. Unlike many other forms of treatment, targeting MK is not expected to harm normal health tissue.
While there are still hurdles to surmount before CDY and Lyramid can proceed to human trials, the further academic validation would be a boon to the company.